Terms: = Sarcomas AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
405 results:
1. fgfr1 fusions as a novel molecular driver in rhabdomyosarcoma.
de Traux De Wardin H; Cyrta J; Dermawan JK; Guillemot D; Orbach D; Aerts I; Pierron G; Antonescu CR
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23232. PubMed ID: 38607246
[TBL] [Abstract] [Full Text] [Related]
2. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract] [Full Text] [Related]
3. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract] [Full Text] [Related]
4. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract] [Full Text] [Related]
5. Synovial sarcoma X breakpoint 1 protein uses a cryptic groove to selectively recognize H2AK119Ub nucleosomes.
Tong Z; Ai H; Xu Z; He K; Chu GC; Shi Q; Deng Z; Xue Q; Sun M; Du Y; Liang L; Li JB; Pan M; Liu L
Nat Struct Mol Biol; 2024 Feb; 31(2):300-310. PubMed ID: 38177667
[TBL] [Abstract] [Full Text] [Related]
6. KSHV vIL-6 enhances inflammatory responses by epigenetic reprogramming.
Inagaki T; Wang KH; Kumar A; Izumiya C; Miura H; Komaki S; Davis RR; Tepper CG; Katano H; Shimoda M; Izumiya Y
PLoS Pathog; 2023 Nov; 19(11):e1011771. PubMed ID: 37934757
[TBL] [Abstract] [Full Text] [Related]
7. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.
Chauhan S; Sen S; Irshad K; Kashyap S; Pushker N; Meel R; Sharma MC
Hum Cell; 2024 Jan; 37(1):297-309. PubMed ID: 37914903
[TBL] [Abstract] [Full Text] [Related]
8. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
9. Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
Bremmer F; Pongratanakul P; Skowron M; Che Y; Richter A; Küffer S; Reuter-Jessen K; Bohnenberger H; Pauls S; Kresbach C; Schüller U; Stühler K; Ströbel P; Albers P; Nettersheim D
Br J Cancer; 2023 Nov; 129(10):1580-1589. PubMed ID: 37726478
[TBL] [Abstract] [Full Text] [Related]
10. Neuropil-like islands are a possible pathogenetic link between glioblastoma and gangliocytoma/ganglioglioma in a case of synchronous bilateral brain tumors.
Ishizawa K; Adachi JI; Tamaru JI; Nishikawa R; Mishima K; Sasaki A
Neuropathology; 2024 Apr; 44(2):126-134. PubMed ID: 37641451
[TBL] [Abstract] [Full Text] [Related]
11. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y;
Lancet Oncol; 2023 Aug; 24(8):925-935. PubMed ID: 37541273
[TBL] [Abstract] [Full Text] [Related]
12. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract] [Full Text] [Related]
13. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone.
Ono T; Noguchi R; Yoshimatsu Y; Sin Y; Tsuchiya R; Akiyama T; Kojima N; Toda Y; Sato C; Fukushima S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2023 Sep; 36(5):1804-1812. PubMed ID: 37328637
[TBL] [Abstract] [Full Text] [Related]
14. fgfr1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and "NTRK-rearranged" spindle cell neoplasms.
Warmke LM; Al-Ibraheemi A; Wang L; Parham D; Rudzinski ER; Stohr BA; Miles C; Habeeb O; Davis JL
Genes Chromosomes Cancer; 2023 Nov; 62(11):641-647. PubMed ID: 37265193
[TBL] [Abstract] [Full Text] [Related]
15. EWSR1 maintains centromere identity.
Kitagawa R; Niikura Y; Becker A; Houghton PJ; Kitagawa K
Cell Rep; 2023 Jun; 42(6):112568. PubMed ID: 37243594
[TBL] [Abstract] [Full Text] [Related]
16. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract] [Full Text] [Related]
17. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.
Li M; Yang L; Chan AKN; Pokharel SP; Liu Q; Mattson N; Xu X; Chang WH; Miyashita K; Singh P; Zhang L; Li M; Wu J; Wang J; Chen B; Chan LN; Lee J; Zhang XH; Rosen ST; Müschen M; Qi J; Chen J; Hiom K; Bishop AJR; Chen CW
Adv Sci (Weinh); 2023 Jun; 10(17):e2206584. PubMed ID: 37075745
[TBL] [Abstract] [Full Text] [Related]
18. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract] [Full Text] [Related]
19. Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.
Zhou J; Toh SH; Tan TK; Balan K; Lim JQ; Tan TZ; Xiong S; Jia Y; Ng SB; Peng Y; Jeyasekharan AD; Fan S; Lim ST; Ong CJ; Ong CK; Sanda T; Chng WJ
Mol Cancer; 2023 Apr; 22(1):69. PubMed ID: 37032358
[TBL] [Abstract] [Full Text] [Related]
20. The usefulness of immunohistochemistry for phosphohistone H3 as a prognostic factor in myxoid liposarcoma.
Takazawa A; Yoshimura Y; Okamoto M; Tanaka A; Kito M; Aoki K; Uehara T; Takahashi J; Kato H; Nakayama J
Sci Rep; 2023 Mar; 13(1):4733. PubMed ID: 36959285
[TBL] [Abstract] [Full Text] [Related]
[Next]
